We manage off-target gene editing risk for biopharma

Invaluable gene editing off-target insights from initial research to patient therapies:

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.

Brands: NoteSeQ; ScopeSeQ; GUIDE-SeQ; ONE-seq